DrugPatentWatch Database Preview
Drugs in Development Information for SHR3162
» See Plans and Pricing
What is the drug development status for SHR3162?
SHR3162 is an investigational drug.
There have been 13 clinical trials for SHR3162.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2020.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Atridia Pty Ltd.
There are two US patents protecting this investigational drug and twenty-one international patents.
Summary for SHR3162
| US Patents | 2 |
| International Patents | 21 |
| US Patent Applications | 3 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2020-04-01) |
| Vendors | 1 |
Recent Clinical Trials for SHR3162
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Fluzoparib in Combination With FOLFIRINOX in Patients With Resectable Pancreatic Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | Fudan University | Phase 2 |
| Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
Clinical Trial Summary for SHR3162
Top disease conditions for SHR3162
Top clinical trial sponsors for SHR3162
US Patents for SHR3162
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SHR3162 | Start Trial | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN) | Start Trial |
| SHR3162 | Start Trial | Methods of using phthalazinone ketone derivatives | Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SHR3162
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SHR3162 | Australia | 2011288876 | 2030-08-09 | Start Trial |
| SHR3162 | Brazil | 112013002220 | 2030-08-09 | Start Trial |
| SHR3162 | Canada | 2806324 | 2030-08-09 | Start Trial |
| SHR3162 | China | 102372716 | 2030-08-09 | Start Trial |
| SHR3162 | China | 102686591 | 2030-08-09 | Start Trial |
| SHR3162 | European Patent Office | 2604610 | 2030-08-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
